8-K: HCW Biologics Reports Q4 and Fiscal Year 2024 Results, Highlights Business Development and Financial Transactions

HCW Biologics announced its fourth quarter and fiscal year 2024 financial results, highlighting business development transactions and clinical development progress.

Summary

• HCW Biologics reported its financial results for the fourth quarter and fiscal year ended December 31, 2024.
• The company is focused on developing immunotherapies for age-related diseases.
• A licensing agreement with WY Biotech is expected to bring in $7.0 million in June 2025.
• The company raised $16.3 million in 2024 through various financing transactions.
• HCW Biologics received an extension from Nasdaq to regain compliance with listing rules by April 28, 2025, for the Bid Price Rule and June 15, 2025, for all other Exchange continued listing rules.
• The FDA cleared the IND for HCW9302 to begin Phase 1 clinical trials for alopecia areata.
• A Phase 2 clinical study evaluating HCW9218 in combination with neoadjuvant chemotherapy in ovarian cancer was closed due to lack of enrollment.
• Revenues for Q4 2024 were $394,804, compared to $1.3 million in Q4 2023.
• Revenues for the year 2024 were $2.6 million, compared to $2.8 million in 2023.
• R&D expenses for Q4 2024 were $1.0 million, a decrease from $2.1 million in Q4 2023.
• R&D expenses for the year 2024 were $6.4 million, a decrease from $7.7 million in 2023.
• G&A expenses for Q4 2024 were $2.0 million, an increase from $1.7 million in Q4 2023.
• G&A expenses for the year 2024 were $6.8 million, consistent with 2023.
• Legal expenses for the year 2024 were $15.9 million, an increase from $6.6 million in 2023, primarily due to arbitration with ImmunityBio.
• The company recognized a $1.3 million loss due to fraudulent activity.
• Net loss for the year 2024 was $30.0 million, compared to $25.0 million in 2023.
• The company has substantial doubt about its ability to continue as a going concern without additional funding.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments such as FDA clearance for a clinical trial and a licensing agreement, the significant net loss, going concern uncertainty, and Nasdaq compliance issues weigh heavily on the overall sentiment.

Positives

• The company received FDA clearance to begin clinical trials for HCW9302 in alopecia areata.
• HCW Biologics has an exclusive worldwide licensing agreement with WY Biotech, expected to generate $7.0 million in June 2025.
• The company raised $16.3 million in 2024 through various financing activities.
• R&D expenses decreased by $1.3 million, or 17%, for the year ended December 31, 2024, compared to the comparable period in 2023.
• The company has constructed 50 proprietary compounds with the TRBC platform for the treatment of hematologic and solid tumors, virally infected cells, and cellular senescence diseases associated with aging.

Negatives

• The company reported a net loss of $30.0 million for the year 2024.
• Legal expenses increased significantly to $15.9 million due to arbitration with ImmunityBio.
• The company recognized a $1.3 million loss due to fraudulent activity.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.
• A Phase 2 clinical study evaluating HCW9218 in combination with neoadjuvant chemotherapy in ovarian cancer was closed due to lack of enrollment.
• The company received deficiency notices from Nasdaq related to its stock price and market value and needs to regain compliance by April 28, 2025, and June 15, 2025.

Risks

• The company's ability to continue as a going concern is uncertain without additional funding.
• Failure to regain compliance with Nasdaq listing rules could result in delisting.
• Clinical trials may not be successful.
• The company may not be able to raise sufficient capital to fund its operations.
• The company's reliance on a licensing agreement with WY Biotech for revenue poses a risk if the agreement is not successful.
• The company's legal expenses related to the arbitration with ImmunityBio could continue to be a burden.

Future Outlook

The company plans additional capital-raising activities in the first half of 2025 and may need to revise its business plan and reduce costs if these activities are not successful. The company believes that substantial doubt exists regarding its ability to continue as a going concern for at least 12 months from the issuance date of the audited financial statements, without additional funding or financial support.

Management Comments

• Dr. Hing Wong, Founder and CEO, stated, 'We are more passionate than ever about our desire to create breakthrough immunotherapeutic treatments for diseases with no known cures, especially pancreatic, ovarian cancer and other age-related diseases.'

Industry Context

HCW Biologics is operating in the competitive biopharmaceutical industry, focusing on novel immunotherapies. The company's focus on age-related diseases aligns with the growing interest in health span and longevity research. The company's business development strategy of out-licensing molecules is common in the industry, especially for smaller companies seeking to leverage the resources of larger pharmaceutical firms.

Comparison to Industry Standards

• HCW Biologics' revenue of $2.6 million is relatively low compared to established biopharmaceutical companies, but is typical for a clinical-stage company.
• R&D spending of $6.4 million is also relatively low, reflecting the company's size and stage of development.
• The net loss of $30.0 million is significant and highlights the challenges faced by early-stage biopharmaceutical companies in funding research and development.
• The company's reliance on licensing agreements for revenue is a common strategy, similar to companies like Xencor and BioNTech, which have successfully partnered with larger pharmaceutical companies.
• The development of the TRBC platform is similar to other companies developing novel protein scaffolds for immunotherapies, such as Harpoon Therapeutics and Maverick Therapeutics.

Legal Proceedings

• The company incurred significant legal expenses related to the arbitration with ImmunityBio and its affiliates.
• The parties entered into a Settlement Agreement and General Release, and the Arbitration and related Complaint were dismissed on December 24, 2024.

Stakeholder Impact

• Shareholders face the risk of dilution from potential capital raises and the risk of delisting from Nasdaq.
• Employees face uncertainty due to the company's going concern issues and potential cost reductions.
• Customers (licensees) may be impacted by the company's financial stability and ability to supply licensed molecules.
• Creditors face increased risk due to the company's financial difficulties.

Next Steps

• Initiate Phase 1 clinical trial for HCW9302 in patients with alopecia areata.
• Obtain stockholder approval for proposals at the Special Meeting on March 31, 2025.
• Regain compliance with Nasdaq listing rules by April 28, 2025, and June 15, 2025.
• Execute additional capital-raising activities in the first half of 2025.
• Share data on TRBC-based molecules in future scientific publications and invited presentations.

Key Dates

Keywords

HCW Biologics, immunotherapies, clinical trials, financial results, licensing agreement, financing, NASDAQ, alopecia areata, cancer, age-related diseases, HCW9302, HCW9218, WY Biotech, TRBC platform